A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

Inclusion Criteria: * 1\. Voluntary signed informed consent and compliance with protocol requirements * 2\. Age ≥18 years, any gender * 3\. Life expectancy ≥12 weeks * 4\. Eastern Cooperative Oncology Group（ECOG） performance status 0-1 * 5\. For Ia monotherapy dose escalation: patients with cytologically and/or histopathologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment * 6\. Voluntary provision of tumor tissue specimens (archived within 2 years or fresh tissue) * 7\. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1（RECIST 1.1） * 8\. Prior anticancer treatment-related toxicities resolved to ≤1 grade (except alopecia) * 9\. Adequate organ and bone marrow function * 10\. Negative serum pregnancy test within 7 days before first dose * 11\. Agreement to use effective contraception from ICF signing to ≥6 months after last dose * 12\. No breastfeeding during study and ≥6 months after last dose * 13\. Understanding of study and voluntary written informed consent Exclusion Criteria: * 1\. Anticancer therapy (chemotherapy, targeted therapy, biologics, immunotherapy, radiotherapy) within 4 weeks before first dose, or participation in other interventional clinical studies (observational studies excluded) * 2\. Strong Cytochrome P450 3A4（CYP3A4）inhibitors within 2 weeks before first dose * 3\. Strong Cytochrome P450 2C8（CYP2C8） inhibitors within 2 weeks before first dose * 4\. Other active malignancies within 3 years before first dose (except curable tumors treated radically) * 5\. Primary Central Nervous System（CNS） tumors or CNS metastases that failed local treatment (stable asymptomatic CNS metastases allowed) * 6\. Conditions affecting drug absorption or Pharmacokinetics（PK） parameters (e.g., uncontrolled nausea/vomiting, chronic diarrhea, malabsorption syndrome) * 7\. Uncontrolled or significant cardiovascular disease, * 8\. Active infection requiring systemic therapy within 2 weeks; * 9\. Major surgery within 4 weeks before first dose (except minor procedures) * 10\. Known allergy to study drug or excipients * 11\. Mental or cognitive impairment affecting study compliance * 12\. Known alcohol or drug dependence * 13\. Pregnant or lactating women * 14\. Investigator deems subject unsuitable for study participation